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Abstract
Background: The success of new sequencing technologies and informatic methods for identifying genes has
made establishing gene product function a critical rate limiting step in progressing the molecular sciences. We
present a method to functionally mine genomes for useful activities in vivo, using an unusual property of a
member of the poxvirus family to demonstrate this screening approach.
Results: The genome of Parapoxvirus ovis (Orf virus) was sequenced, annotated, and then used to PCR-amplify its
open-reading-frames. Employing a cloning-independent protocol, a viral expression-library was rapidly built and
arrayed into sub-library pools. These were directly delivered into mice as expressible cassettes and assayed for an
immune-modulating activity associated with parapoxvirus infection. The product of the B2L gene, a homolog of
vaccinia F13L, was identified as the factor eliciting immune cell accumulation at sites of skin inoculation.
Administration of purified B2 protein also elicited immune cell accumulation activity, and additionally was found to
serve as an adjuvant for antigen-specific responses. Co-delivery of the B2L gene with an influenza gene-vaccine
significantly improved protection in mice. Furthermore, delivery of the B2L expression construct, without antigen,
non-specifically reduced tumor growth in murine models of cancer.
Conclusion: A streamlined, functional approach to genome-wide screening of a biological activity in vivo is
presented. Its application to screening in mice for an immune activity elicited by the pathogen genome of
Parapoxvirus ovis yielded a novel immunomodulator. In this inverted discovery method, it was possible to identify
the adjuvant responsible for a function of interest prior to a mechanistic study of the adjuvant. The non-specific
immune activity of this modulator, B2, is similar to that associated with administration of inactivated particles to a
host or to a live viral infection. Administration of B2 may provide the opportunity to significantly impact host
immunity while being itself only weakly recognized. The functional genomics method used to pinpoint B2 within
an ORFeome may be more broadly applicable to screening for other biological activities in an animal.
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Introduction
Bioinformatic analyses of microbial sequences have chan-
ged the way searches for vaccine antigens can be con-
ducted; researchers can avoid pathogen isolation, culturing,
and fractionation as a means of target identification. How-
ever these “reverse vaccinology” approaches [1], in which
sequences are evaluated relative to their likelihood of
encoding protective antigens, carry some limitations such
as i) our poor understanding of the characteristics of a
pathogen component that make it protective and ii) the
inability to query the substantial proportion of any micro-
bial genome that carries no previously described homologs
or motifs [2]. Therefore, empirical approaches to rapidly
determine the natural functions or non-natural applica-
tions of genome-encoded products are needed [3]. Toward
this purpose, there has been some progress in using gen-
ome databases to recombinantly produce proteins in cell
culture or test tubes for printing nanoscale quantities onto
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glass microscope slides [4]. These protein arrays can be
used to perform rapid, parallel in vitro screens if a slide-
compatible functional assay is available. Genome-wide
screening in mammalian cells using RNA interference and
expression libraries has also gained much popularity [5].
However, these platforms do not provide the opportunity
to assay activities at the organism level, such as an animal’s
immune activity.
We previously described an approach to vaccine antigen
discovery that, similar to reverse vaccinology, does not
require pathogen culturing but in contrast does not rely
on bioinformatic analyses nor require recombinant protein
production. Instead, it is based on the delivery of each
gene in vivo and its direct functional testing as a vaccine
candidate in host animals. Using expression library immu-
nization (ELI) [6], pathogen genomes can be searched for
protective antigens in streamlined multiplexed animal
challenge assays [7-9]. Here, this parallel-testing strategy is
extended for use in searching for any measurable biologi-
cal activity encoded by a gene in vivo. It uses genomic
sequence information to prepare genes for rapid and
unbiased isolation of biological effectors. As demonstra-
tion, we chose a pathogen with a novel immune activity of
potential application for therapeutic immune-modulation.
The Poxviridae Family includes many well-known
pathogens. They carry complex genomes that encode a
variety of mechanisms for subverting the immune
responses of infected hosts [10]. The globally prevalent
Parapoxvirus ovis (ORFV) causes Orf, an acute and highly
infectious disease largely limited to sheep and goats, but
which can be also transmitted cutaneously to people hand-
ling infected animals [11]. Epithelial infection leads to the
development of pustular skin lesions and then scabs [12].
Virus is shed from the scab and no systemic spread occurs.
Despite lesion repair and an initial vigorous inflammatory
response, the ORFV-specific host immune response is
transient and ineffective in viral neutralization, perhaps
due to its unique immune regulation and skin epithelial
niche [13]. Consequently, re-infection of the same host is
common [14,15]. Administration of whole inactivated
virus (iORFV) similarly shows clinical effect [16] and fails
to prevent subsequent infections, rendering a conventional
vaccine design against Orf disease impractical. However,
these inactivated preparations hold strong immune-stimu-
lating properties including transient interferon-gamma
(g-IFN) induction followed by autoregulatory T helper 2
cell cytokine activity that is not antigen specific [15,17-19].
Inactivated virus provides short term, non-specific
immune protection against a number of viruses [16,17],
and is sold as Baypamun (Bayer, Inc.), or more recently as
Zylexis (Pfizer AH, Inc.), to prevent disease in herds dur-
ing short periods of close confinement and stress, such as
during transport and regrouping [20].
Failure of a host to sustain specific immunity against
ORFV infection may relate to the effect of the infection on
the skin’s epidermal Langerhans and dermal dendritic cells
(DC). ORFV has the ability to manipulate these antigen
presenting cells (APCs) cells, central to initiating both
innate and adaptive immune responses [21,22]. Histologic
examination of pock lesions demonstrates that the sites of
infection become densely packed with DC within two to
four days of virus exposure [23]. Since they appear to be
recruited and detained rather than having migrated away
as would be expected following antigen exposure, they
serve as a barrier to systemic infection and cannot initiate
an adaptive response because they do not gain access to T
cells in the lymph nodes. Furthermore, when the skin
lesions fully resolve the DC are concomitantly sloughed
off [23]. These observations suggested that ORFV carries
one or more factors that are able to recruit and/or retain
DC at the skin. One or both of these immune-related
activities may contribute to the unusual characteristics of
ORFV infection. Notably, iORFV inoculation does not sti-
mulate DC accumulation yet does initiate a strong inflam-
matory cytokine response and transient non-specific
immunity. Isolation of the putative immune-cell modulat-
ing component(s) might provide useful research and bio-
medical applications for it.
To mine the ORFV genome empirically for the immune-
cell regulator gene(s) that cause the accumulation of DC-
like cells at a site of skin inoculation, the genomic
sequence of the ORFV strain used in the Baypamun and
Zylexis products, D1701, was determined. This complete
yet low coverage sequence information was used to specify
oligonucleotide (oligo) primers for the amplification of all
predicted open reading frames (ORFs). This ORFeome
was placed in linear expression elements (LEEs) [24] and
delivered into mice to directly assay for the desired innate
immune activity. The B2L gene was identified as eliciting
DC-like cell accumulation and also other immune-modu-
lating activities. Regulation of DC-like cells might be gen-
erally useful in vaccination or other immunomodulation
strategies [25]. This approach of screening a library direct-
ing in an animal for a biological activity may have further
utility.
Results
Sequence determination
The D1701 isolate of Parapoxvirus ovis (ORFV) was used
to prepare the immune-stimulating product Baypamun;
therefore, genomic (g)DNA from this virus was obtained
(gift from Tobias Schlapp, Bayer). The viral gDNA was
shotgun cloned for sequencing. The final assembly con-
sisted of 134,040 nucleotides and is reported [Genbank:
HM133903]. Three complete ORFV (Orf) genomes are
available in the NCBI database (OV-NZ-2, OV-IA82, and
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OV-SA00). The NZ-2 strain is most closely related to
D1701, with > 95% nucleotide sequence identity. The
majority of the differences between the sequences of
D1701 and NZ-2 are found toward the flanking terminal
repeat regions. An electronic MacVector Genescan
course analysis of the assembled D1701 genome using a
minimum ORF encoding length of 90 aa yielded 288
putative proteins. The annotated ORFV genomes in
NCBI each have only 134 identified ORFs, indicating that
our parameters are relaxed. We chose not to modify
these determinations so as to be most inclusive and use
the functional screen to eliminate non-ORFs. Sequence
comparison (BLAST) of the D1701 strain to the NZ-2
ORFV strain identified three additional putative ORFs;
these were added to the list to obtain a total of 291
sequences to explore. We determined that D1701 B2L
was not recognized in our annotation because of a single
base sequencing error that created a predicted frameshift
at amino acid position 126 and a stop codon at aa posi-
tion 299. Whereas this led to the design of a shortened
ORF that appeared to encode a divergent aa sequence,
the NZ-2 sequence comparison enabled us to identify the
sequencing error and retrieve the wild type full length
ORF. The B3L gene homolog had not been designated as
an ORF because the translated product contains only 89
amino acids and our algorithm required a minimum of
90 amino acids; the B3L gene [26] was included in the
screen.
Functional screening of an ORFV library for immune cell
recruitment activity
The viral ORFeome screening strategy is illustrated in
Figure 1. Based on the sequence annotation, 257 parapox-
virus ORFs were successfully PCR-amplified and these
were randomly distributed into 27 pools of 8 to 10 ORFs
each. All ORF pools were non-covalently linked to a mam-
malian promoter and termination element to obtain LEEs
as previously described [24]. Since ORFV does not infect
rodents, mice cannot serve as a model of host infection;
however, they can serve as hosts for exploration of ORFV-
elicited immune activity. The 27 pools were biolistically
delivered into separated skin sites on the abdomen of
BALB/c mice. Each mouse was inoculated by gene gun
(shot) with 4 to 6 pools; each pool was delivered to 3 dif-
ferent mice. Four days after inoculation, the mice were
sacrificed and the shot sites were harvested. Tissue sec-
tions were screened for DC-like cell accumulation by
immunostaining cryo-slices for major histocompatibility
(MHC) class II positive cells (anti-I-Ad/I-Ed antigen reac-
tivity). While multiple cell types in addition to dermal and
epidermal DC have been identified within the skin that
stain positively for MHCII I-A/I-E expression (namely
macrophages, endothelial cells, and some T cell subclasses
[27,28]), the positively staining cells appeared with DC-like
cell morphology. Therefore, any newly observed I-A+/I-E+
cell staining is expected to include the migratory DC,
although other resident, non-migratory immune cell types
will also contribute. A skin site inoculated with a LEE-
encoding luciferase (LUC) was used both to normalize
gene delivery efficiency and to serve as an irrelevant (non-
ORFV) gene-inoculated tissue section. Viral infection
could not serve as a positive control since mice are not
hosts, and the inactivated virus preparation has been
shown by us and others not to stimulate immune cell
accumulation.
The densities and morphologies of anti-I-A/I-E-visua-
lized MHC class II-positive cells were similar among the
bombarded tissue samples save for those shot with ORF-
pool X. This is displayed in representative samples shot
with pools I, J, and K as compared to pool X (Figure 2,
right column). The pool X-shot tissue sections exhibited a
more diffuse and higher level of staining relative to sites
inoculated with any of the other 26 pools, an irrelevant
luciferase (LUC) LEE, or even unshot skin (Figure 3b,
right panel and unpublished results). Thus, pool X
appeared to contain a gene whose product modified the
accumulation and/or distribution of MHC II+ cells. The
same four tissue sections are shown under white light
microscopy to visualize microparticles so as to compare
delivery efficiencies among pool tests (Figure 2, left col-
umn). Comparison of left and right columns can also be
used to assess positions of gold particles relative to posi-
tions of I-A+/I-E+ cells.
Pool X was comprised of eight ORFs; this included the
three ORFs identified by comparison to the NZ-2 strain
sequence (B2L, B3L and vIL10). The remaining five were
predicted from the D1701 sequencing results (270, 272,
277, 278, and 279). The NZ-2 B2L gene product had
been previously identified as the homolog of the vaccinia
(VACV) virus major envelope antigen gene, F13L [26,29].
The truncated D1701 B2L ORF described above resided
in pool J, which did not induce the accumulation of I-A+/
I-E+ cells (Figure 2a). Pool J was retested multiple times
in multiple mice to confirm this negative result (data not
shown).
The effect of each of the ORFs comprising pool X on
immune cell accumulation was tested by delivering them
separately (1 μg/ORF) at distinct sites on the abdomen of
mice, in triplicate. The original X pool and a LEE expres-
sing the LUC ORF were retested as positive and negative
controls, respectively (data not shown). The tissue sec-
tions removed from each inoculation site were stained
for anti-I-A/I-E antibody reactivity (Figure 3a). Skin sec-
tions inoculated with the ORF encoding B2 displayed
increased densities of MHC class II positive cells relative
to control tissues (Figure 3a). In a confirmatory experi-
ment, both white light and fluorescent images of the
same B2L-shot tissue section were visualized so that
McGuire et al. Proteome Science 2012, 10:4
http://www.proteomesci.com/content/10/1/4
Page 3 of 16
Parapox ovis
27 Groups of 
8-10 LEES
Immuno-stain, Visualize
+
ORFs
Prom
Term
}
Figure 1 An in vivo strategy for functionally searching the parapoxvirus ovis genome for useful ORFs. The genomic sequence of
parapoxvirus ovis (ORFV) strain D1701 was determined, and ORFs were identified. Sequence results were used to design PCR primers for gene
amplification. The library of parapoxvirus ORFs (ORFeome) was generated and then partitioned into 27 pools of 8 to 10 ORFs each. Mammalian
promoter and terminator expression elements were added to each pool, treated to expose single stranded end sequences, and then assembled
into LEEs by sequence specific annealing. The ORF-expressing LEE pools were precipitated onto gold microparticles and biolistically delivered
into the abdomen skin of BALB/c mice. To limit the number of animals used, each mouse was gene-gun inoculated with four to six different LEE
pools at distinct abdominal sites. Each pool was tested in triplicate, in 3 different mice. Tissue sections were harvested 4 days later, cryo-sliced
and immuno-probed to identify MHC II expression (I-Ad/I-Ed) and visualize cell morphology.
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Figure 2 Screening an ORFV expression library for genes encoding products that direct accumulation of MHCII-positive cells. Left
panels. Light microscope view pool-inoculated tissue sections, showing the distribution and density of gold microparticles delivered to cells by
gene gun. Right panels. Tissue sections prepared from the same pool-inoculated mouse skin shown in left panel were stained with FITC-labeled
antibody 2G9 (anti- I-Ad/I-Ed) to visualize I-A+/I-E+ immune cells. Each panel shows skin samples obtained 4 days after gene gun inoculation with
pools of mixed-ORFs (2 μg of total pool DNA per site). Tissue staining densities within sections harvested from mice inoculated with pools I, J,
and K are representative of all but X. The sections obtained from the mice shot with pool X displayed an increase in staining. Scale bars are
200 micron.
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immune cell localization and gun microparticle distribu-
tion could be compared (Figure 3b, left and middle
panels). As indicated by the fluorescent image in the mid-
dle panel, inoculation of abdominal skin with the full
length B2L ORF- D1701 led to DC-like cell accumulation
relative to unshot tissue (Figure 3b, right panel).
B2 protein displays immune cell accumulating and
adjuvant-like activities
The D1701 B2 protein was recombinantly expressed and
affinity-tag purified. A yeast protein, SRB4, was pro-
duced in the same E. coli expression vector and purified
in the same manner in parallel to serve as an irrelevant
protein control. When intradermally (i.d.) injected into
mouse abdominal skin, recombinant (r)B2 protein led to
the accumulation of DC at the site of inoculation with
efficiency similar to that seen following genetic inocula-
tion (Figure 4a and 3). Neither an irrelevant recombi-
nant protein (Figure 4a) nor the buffer control (data not
shown) increased the local density of DC-like cells. For
comparison, rB2 from the ORFV isolate NZ-2 was also
produced and purified. Injections of this protein also eli-
cited DC-like accumulation at the skin site (Additional
file 1).
In an immunization experiment, mice were i.d.
injected with i) rHBsAg protein only, or co-injected
A.
B.
fluor/ unshot
wh light/ B2L fluor/ B2L
Figure 3 Testing of individual ORFs comprising parapoxvirus library pool X identifies the B2L gene. The ORF-expressing LEEs from pool
X were inoculated individually into mouse abdomen sites using the gene gun (1 μg LEE per site), in triplicate, and skin sections were obtained
4 days later. Samples were processed and immuno-stained for the MHC II surface marker I-Ad/I-Ed with antibody 2G9. Scale bars are 200 micron.
A. Immunostains of tissue sections from ORFV ORF-expressing LEEs comprising pool X. Viral gene numbers are indicated alongside
corresponding skin sections. Each of the eight representative tissue sections is presented as an overlay of FITC labeled anti-I-Ad/I-Ed fluorescent
microscopy. B. The same section of skin inoculated with B2L was viewed under both white visible (wh) light to observe gold particles (left
panel) and under fluorescence (fluor) to visualize FITC-labeled class II positive cells (I-A/I-E+) (middle panel). An untreated section of skin was
stained with FITC labeled anti-I-A/I-E and visualized under fluorescence (fluor) (right panel).
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with ii) rHbSAg + rSRB4 (control), or iii) rHbSAg + rB2.
Administration of rHBsAg by itself or with the rSRB4
protein control (rCTRL) did not stimulate a significant
anti-HBsAg antibody response. However, co-immuniza-
tion with rB2 stimulated a strong antibody response
(Figure 4b). For example at day 56, rHBsAg alone gener-
ated titers significantly lower than that generated by
rHBsAg + rB2, p = 0.029. Similarly, rHBsAg + rCTRL
generated titers significantly lower than that generated
by rHBsAg + rB2, p = 0.032. To explore the possibility
Figure 4 The B2 protein directs accumulation of immune cells and enhances an antigen-specific antibody response. A. Mice were
injected i.d. in the abdomen with 50 ng of the irrelevant recombinant (r)SRB4 protein (rCTRL) (left panel) or recombinant (r)B2 protein (right
panel); the 2 proteins were injected into separate abdominal sites of 3 mice. Both proteins were produced in E. coli by the same protocol and
identically purified. After 4 days, immune cell densities were measured in harvested skin by 2G9 immuno-staining, as described in Figures 2 and
3. Scale bars are 40 micron. B. Mice were co-injected i.d. in the abdomen with 1 μg rHBsAg alone (▲), 1 μg rHBsAg with 50 ng of rB2 protein
(●), or 1 μg rHBsAg with 50 ng of the rSRB4 control protein (rCTRL) (O). Sera collected over a 2 month time-course were assayed for antibodies
to HBsAg by ELISA, with an HRP-readout as described in Material and Methods. No boosts were administered. Antibody levels of experimental
samples were calculated relative to absorbance (A450) values measured for known amounts of a commercial anti-HBsAg antibody (Seradyn, Inc).
Calculated antibody levels are plotted; error bars are SDs from the arithmetic mean. Student’s t-test was used to compare antibody levels at
day 56.
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of an antibody response to the adjuvant itself, these
same sera were also tested in an ELISA against rB2 as
antigen. No reactivity to B2 was detected by ELISA
(Additional file 1) or immunoblot, when it had been
administered to the mice in either protein-format (Addi-
tional file 2) or gene-format (data not shown).
B2L as modulates infectious and noninfectious
disease. models
The ultimate goal of an immunization is to provide protec-
tion against disease. Therefore, the effect of co-delivering
pCMVi-B2L as an adjuvant for an influenza gene vaccine
was evaluated in a viral protection assay. Mice were admi-
nistered a construct expressing the protective hemaggluti-
nin (HA) gene (pCMVi-HA) in a dosage series of 0.4 ng,
4 ng, 40 ng, and 400 ng total mouse dose along with a 1 μg
total mouse dose of either pCMVi-B2L, pCMVi-mGMCSF,
or a control plasmid (pUC119). The same inocula were
administered three weeks post-prime; at six weeks post-
boost all animals were challenged with a lethal dose of
influenza A virus and survival was monitored daily. When
the vaccine was delivered with only the control plasmid,
even the highest dose of pCMVi-HA did not protect 50%
of the mice from viral challenge. By contrast mice co-
immunized with pCMVi-HA and a plasmid expressing
either i) B2L or ii) the established genetic-adjuvant
GMCSF were fully protected. This vaccine enhancing effect
was antigen dose dependent. At the intermediate pCMVi-
HA doses, co-delivery of either the murine GMCSF gene
(4 ng) or B2L gene (40 ng) conferred a protective trend
relative to the control vaccine. At the lowest vaccine dose
(0.4 ng), only 20% of the animals survived in all three
groups indicating that both the B2L and positive control
adjuvant expressing plasmids were unable to enhance the
antigen-directed protection at this dose. As displayed in
Figure 5, a log-rank survival analyses of the Kaplan-Meier
curves indicates a significant difference between the adju-
vanted and unadjuvanted gene vaccine at 400 ng (p = 0.01).
In addition to infectious diseases, vaccines can be envi-
sioned to defend against non-infectious diseases such as
cancer; however, common tumor-specific antigens are dif-
ficult to identify. Using a murine transplantable model of
an aggressive melanoma cancer, we tested the possible
effect of pCMVi-B2L, without a co-delivered antigen, as a
non-specific defense against tumor development. Two
groups of 20 C57BL/6 mice were injected subcutaneously
(s.c.) with the B16 sub-line B16-F10. The following day,
the test group was genetically immunized with the mam-
malian expression plasmid pCMVi-B2L and the control
group received the empty vector (pCMVi). Palpable
tumors were detected at day 6 post cell injections; tumor
dimensions were measured at days 8, 10, and 13. Calcu-
lated volumes plotted in Figure 6 show a significant reduc-
tion in the tumor sizes in the pCMVi-B2L immunized
mice relative to vector only controls (p = 0.013). Sacrificed
animals were recorded through day 25, establishing a sig-
nificant difference in survival curves (p = 0.008). Immuni-
zation of BALB/c mice with a similar B2L expression
plasmid (pPCR3.1-B2L) led to a modest but measureable
reduction in tumor sizes 20 days following injection of the
breast cancer cell line 4T1 (p = 0.036) (data not shown).
Discussion
New genomic sequence information from a pathogen was
rapidly converted into gene function data using a direct
screen for biological activities of interest. This was accom-
plished by taking advantage of linear gene expression, a
multiplexed pooling strategy, and genetic immunization.
In this example screen, a genome was queried for an
immunomodulating activity; however, a similar strategy
could be applied to query any genome for any gene-encod-
ing activity for which one can design a bio-assay. The low
coverage sequencing reads performed in this work were
sufficient to identify all ORFs and design primers for PCR.
Higher coverage reads would afford the opportunity to
synthetically build genomes, and thereby further eliminate
the need for culturing pathogens even if only for genomic
DNA template production. As time and cost of both large
scale sequencing and gene building continue to decrease,
this latter approach is increasingly attractive.
A parapoxvirus ovis gene responsible for the manipula-
tion of host immunity was initially identified in days, using
less than 30 mice. In particular, expression of the ORFV
B2L gene was found to elicit the accumulation of DC-like
cells at the site of skin inoculation. We did not establish
whether this accumulation is a result of immune cell
retention or recruitment. Dermal and epidermal (Langer-
hans) DC are distributed in lattice-like patterns within the
skin [30,31], comprising an estimated 10% of the dermal
cells [27]. This lattice is observed when untreated mouse
skin is immuno-stained for MHC II-expressing cells.
When skin is bombarded with gold microparticles, many
of the DC disappear from the shot skin site [32,33]. These
cells react to bombardment by migrating to the draining
lymph node where they can activate T cells and other
immune cells [34,35]. Microparticle densities visualized
under white light appeared similar among the many tissue
sections bombarded with particles carrying a pool of LEEs.
However, migrating DC represent only a portion of I-A
+/I-E+ skin cells, therefore their loss, or lack of loss, may
not be measureable. More informatively, overlaying of the
white light and fluorescent views of the shot tissue sec-
tions indicate that skin samples shot with either pool X or
the individual B2L gene display significant areas of fluores-
cence that do not correlate with the position of a particle.
Whereas, samples shot with other pooled or individual
constructs displayed a close correspondence between par-
ticles and fluorescence (Figure 2 and 3). These results
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indicate that non-resident I-A+/I-E+ immune cells were
recruited to the shot site after bombardment with B2L.
Non-resident DC have been previously shown to be
recruited to a skin site upon ORFV infection [23].
Relative to other resident skin cell types, MHC II-posi-
tive DC are the most potent initiators of an immune
response [33]. However, the increased density of DC at an
immunization site could influence the generation of a sub-
sequent adaptive response with several possible outcomes.
For instance, by causing resident DC to be retained and
others further recruited to the skin rather than homing to
the draining lymph node, an immune response might be
diminished. Alternatively, maintaining the DC at the
immunization site may provide additional opportunity to
process antigens synthesized by neighboring cells such as
keratinocytes before eventually migrating to the lymph
node, thus initiating a stronger immune response. Finally,
B2L co-delivery with an antigen may have no effect on the
antigen specific response.
We showed that co-delivery of B2 protein with an anti-
gen (HBsAg) elicited enhanced levels of antigen-specific
antibodies (Figure 4). Protective immunity elicited by an
influenza gene vaccine was also enhanced by co-adminis-
tration of the B2L gene (Figure 5). In a gene vaccine dose
p= 0.01
pHA=40ng
pHA=4ng
pHA=400ng
pHA=0.4ng
Figure 5 Protective immunity against influenza virus conferred by a hemagglutinin gene vaccine is enhanced by co-administration of
the B2L gene. Groups of BALB/c mice were immunized with a series of pCMVi-HA (pHA) doses: 0.04 ng, 4 ng, 40 ng, and 400 ng, as indicated
above each graph, and represent total mouse doses which were delivered in 2 gene gun discharges (shots). This gene vaccine plasmid (pHA)
was co-delivered with 1 μg pUC119 as a negative control plasmid (pCTRL) (short dashes), 1 μg pCMVi-B2L (pB2L) (solid line), or 1 μg pCMVi-
GMCSF (pGMCSF) as a positive control plasmid (long dashes), delivered in 2 shots. Animals were given a second immunization with the same
inocula and dose 3 weeks post-prime. Mice were challenged with a lethal intranasal dose of influenza A virus 6 weeks after the boost. All mice
in the control, unimmunized group died on or before day 12. The Kaplan-Meir survival curves for each group of mice (8 mice per group) are
displayed. A parametric survival test (Prism 4, Graphpad, Inc.) was used to measure significant differences between survival rates observed at the
400 ng HA gene vaccine dose.
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titration, a positive trend for adjuvanted protection was
observed at intermediate vaccine doses but not the lowest
dose, indicating protection was antigen specific and dose
dependent. We additionally found that gene gun adminis-
tration of the B2L expression construct to mice, without
an antigen expressing construct, was able to reduce the
rate of tumor growth in a transplantable model of cancer
(Figure 6). The non-specific protection provided by B2L is
reminiscent of the short-term protection conferred by
either live ORFV or iORFV against viral infections; how-
ever, iORFV does not also cause I-A+/I-E+ cell accumula-
tion, as do B2L and live virus. This seems to suggest that
delivery of B2L is immunologically more similar to live
infection than delivery of whole inactivated virions.
Delivery of the B2L expression construct arguably pro-
vides three possible effector molecules for the observed
immune activities: DNA, RNA, and protein. However,
delivery of the DNA construct carrying a full length B2L
gene but expressing a truncated B2 protein did not hold
modulating activity, whereas direct delivery of purified
full length B2 protein did (Figure 4, Additional file 1).
These results indicate that the B2 protein is the relevant
effector molecule, and that the effector activity requires
the C-terminal portion of the protein.
Neither the mechanism of B2-induced accumulation of
immune cells nor its mechanism of enhancing specific or
non-specific responses is clear. However, informatics
analyses are suggestive. B2 is the homolog of vaccinia
virus (VACV) F13, also called p37 [26], which carries a
number of known features. This palmitoylated protein is
the major antigen on the surface of enveloped virions,
and is required for viral envelopment and egress [36].
F13 is one of seven virus-encoded envelope proteins
which is present in the intracellular enveloped virus
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Figure 6 Immunization with the B2L gene reduces tumor growth in a murine model of aggressive melanoma. Two groups of 20 C57BL/
6 mice were injected s.c. with 5 × 104 B16-F10 cells. Twenty-four hours later, the test group (●) was biolistically administered pCMVi-B2L to both
sides of both ear pinnae (4 shots of 0.5 μg totaling 2 μg per mouse). The control group (O) was administered the same dose of empty vector
(pCMVi). Animals were monitored daily; on day 6, tumors were palpable and these were measured in triplicate by two individuals. Tumor growth
was similarly measured and recorded on days 8, 10, and 13. Average tumor sizes within each group are plotted; error bars represent SDs from
the arithmetic mean. Survival curves for the same mice are displayed as an inset with a p value derived to statistically compare control and B2L-
immunized groups (Prism4 software, Graphpad, Inc.).
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(IEV), cell-associated enveloped virus (CEV), and extra-
cellular enveloped virus (EEV) [37]. Two others of these
seven VACV envelope proteins, B5 and A33, are compo-
nents of the “4-pox” subunit vaccine candidate for small-
pox [38]. A33 targets F13 to the IEV, and these two
proteins immunoprecipitate as an A33/F13 complex
from infected cell lysates [39]. Proteins F13 and B5 co-
localize forming a disulfide bonded complex that is
required for efficient and complete wrapping of the intra-
cellular mature virus [29,37,39].
ORFV is unique relative to VACV and other orthopox-
viruses in its lack of any B5 homolog. Perhaps the lack of
an homologous B5/F13 complex is relevant to the unique
immune cell accumulation activities of ORFV. By contrast,
an A33 homolog does exist in ORFV. Stage-dependent
trafficking of B2 by an A33 homolog during the ORFV
infection cycle might be relevant to the immune cell accu-
mulating activity of live-virus and purified B2, which
iORFV preparations such as Baypamun, lack. Inactivated
virions represent one snapshot of surface protein land-
scapes, whereas a live virus could cycle proteins to and
from the surface.
Vaccinia F13 carries a conserved HKD-like motif that is
found in members of the phospholipase D (PLD) gene
superfamily, which encodes the catalytic site for phospho-
lipase activity or simply a lipid binding site [40]. Lipids
play a regulatory role within the immune system [41].
Mammalian PLDs have been well studied because of their
role in membrane vesicular trafficking and critical signal
transduction cascades [37]. Mutation of the HKD-like
motif in F13 of VACV leads to loss of cell to cell viral
spreading, indicating that it is an active superfamily mem-
ber. It appears to encode a lipid binding rather than modi-
fying activity [40], such as do toll-like receptors. Notably,
this C-terminally-located PLD domain is found at aa posi-
tions 318-342 of B2. In our experiments, the initially
designed B2L ORF did not display immune I-A+/I-E+ cell
accumulation activity in our expression screen. This trun-
cated ORF was amplified from D1701 gDNA, therefore it
carried the correct sequence, not the sequencing error at
aa position 126. However, the prematurely positioned 3’
primer caused a truncation at position 299 (because the 3’
primers of the library were all designed with in-frame stop
codons).
B2L of ORFV strains D1701 and NZ2 differ at the
nucleotide level at only 32 of 1134 nucleotides and at the
protein level there are only 9 aa substitutions. Table 1 dis-
plays the protein sequences encoded by the two B2L
genes. The C terminus is invariant; there are no amino
acid changes in the PLD-related region of the protein. By
contrast there are several aa changes relative to the C ter-
minus of VACV F13, as highlighted in Table 2. These
comparisons are consistent with a distinction between
activities of the VACV versus ORFV homologs. While
VACV infection does not lead to immune cell accumula-
tion, we did not evaluate the activity of VACV F13 in iso-
lation; therefore, we cannot ascertain whether or not it
independently carries B2-like modulatory activity.
Further work will explore whether B2 is responsible for
any other activities related to the immune system. For
example, B2 may stimulate the uptake of exogenous anti-
gen or stimulate chemokine activity. As a read-out of an
adaptive response, we have used antibody reactivities.
Since B2L administration enhanced the effectiveness of a
viral gene vaccine it may also influence cellular mediated
immune activities. The effect of B2L expression on tumor
development in the absence of antigen suggests a non-
specific immunity is elicited against a chronic disease.
Testing B2L administration prior to an infectious chal-
lenge will determine whether this molecule alone can also
protect against an acute disease.
Conclusions
A novel immunomodulator, B2, was isolated from an Orf
virus in a functional screen of its ORFeome. B2 was identi-
fied by its effective accumulation of immune cells at a site
of inoculation. However several practically significant
activities were also established. B2 performs as an enhan-
cer of antigen specific immunity, it acts as a non-specific
immune enhancer in the absence of an antigen, and it is
itself non-immunogenic.
Whereas mechanistic studies are typically performed as
a means to the identification of a factor responsible for a
given activity, the functional genome mining approach
presented here enabled the factor to be identified and iso-
lated before its mechanism of action was explored.
Mechanistic studies can now be conducted with better
molecular tools. Characterizing B2 and its activities should
facilitate our ability to modulate and control immune
responses. Recent trends in vaccine development are
aimed at identifying subunit vaccines rather than produ-
cing the conventional whole-pathogen based ones. This
creates a greater need for developing a toolbox of safe
adjuvants to compensate for the reduced immunogenicity
of the pure component formulations.
Methods
Reagents
Purified parapoxvirus ovis DNA (D1701 strain) was
obtained from Tobias Schlapp of Bayer Pharmaceuticals,
Germany. Female BALB/c and A/J mice were purchased
from Harlan Laboratories (Indianapolis, IN). Oligo primers
for PCR amplification of individual ORFs were synthesized
in house using either an ABI synthesizer or the MerMade3
high throughput synthesizer [42]. The ORFV-specific pri-
mers were designed with a common 15 nucleotide
sequence at the 5’ends carrying 5 deoxy-uracil (dU) bases.
Distinct dU-containing sequences were designed for the
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forward and reverse primer sets. After PCR amplification,
the dU stretches can be removed by treatment with uracil-
DNA glycosylase (UDG), exposing defined 3’ overhanging
sequences. These single-stranded regions are designed to
hybridize to complementary overhangs, similarly gener-
ated, on PCR products carrying a CMV promoter and
hGH terminator [43] FITC-conjugated rat anti-I-Ad/I-Ed
antibody (2G9), rat anti-I-Ak antibody (11-5.2) and unla-
belled rat anti-CD16/CD32 (Fc block, 2.4G2) were pur-
chased from Pharmingen (San Diego, CA). Rat IgG was
purchased from Jackson Laboratories (West Grove, PA).
Tissue Freezing Medium (Triangle Biomedical Sciences,
Durham, NC) and Superfrost Plus microscope slides were
obtained from Fisher Chemical Co (Norcross, GA). Vecta-
shield fluorescence microscopy mounting medium was
obtained from Vector Laboratories (Burlingame, CA).
Sequencing of ORFV D1701
The D1701 viral genomic (g)DNA was digested with
BamHI and BglII then cloned into the pUC118 vector [44].
Random clones from this library were sequenced from
both ends. Sequencing reads were assembled and gaps
filled by walking into library clones with primers generated
against newly determined sequence or by PCR amplifica-
tion from intact ORFV genomic DNA. Sequence coverage
varied from a minimum of 3 to over 50 reads per segment,
which would be considered a relatively low resolution
determination. The final assembly consisted of 134,040
nucleotides with 32 ambiguous positions. The terminal
repeat sequences at the ends of the viral genome appear to
be incomplete in the random library. These were not
resolved because in all three currently sequenced Orf
viruses there is at least 2400 bp from the reported ends to
the first or last protein coding segment.
Production of ORFV genes and expression element
components
The sequence of the 134 kb ORFV genome was searched
for ORFs using the MacVector Genescan sequence analy-
sis program. The parameters were set such that each ORF
required a start and stop codon and encoded a protein
with a minimum length of 90 amino acids (aa). The search
included both strands, in all possible reading frames and
did not exclude overlapping reading frames. This search
yielded 288 possible ORFs. In addition, three full-length
protein-coding sequences from the NZ-2 strain of ORFV
virus were present in the NCBI sequence database that
were similar to D1701 sequences that we had not anno-
tated as ORFs. We prepared primers based on the NZ-2
sequences and amplified these regions of D1701 for inclu-
sion in the library. ORFV-specific primer sets were
designed and synthesized for all D1701 ORFs.
PCR products were obtained using the following condi-
tions. Each 50 μl reaction contained 10 pmol of forward
and reverse primer, 5 ng ORFV genomic DNA template,
10 mM Tris-HCl, pH 8.8, 50 mM potassium glutamate,
2 mM MgCl2, 0.2 mM dNTP, 1 M betaine and 2.5 U Taq
polymerase. Each reaction was overlaid with mineral oil
and incubated according to the following parameters in a
Strategene Robocycler. An initial cycle consisted of 3 min
Table 1 Sequence comparison of the B2 protein of ORFV strains D1701 and NZ21,2
D1701_B2 MWPFSSIPVG AQCRVLETLP AEVASLAQGN MSTLDCFTAI AESAKKFLYI CSFCCNLSST
NZ2_B2 MWPFSSIPLG ADCRVVETLP AEVASLAQGN MSTLDCFTAI AESAKKFLYI CSFCCNLSST
D1701_B2 KEGVDVKDKL CTLAKEGVDV TLLVDVQSKD KDADELRAAG VNYYKVKVST REGVGNLLGS
NZ2_B2 KEGVDVKDKL CTLAKEGVDV TLLVDVQSKD KDADELREAG VNYYKVKVST KEGVGNLLGS
D1701_B2 FWLSDAGHWY VGSASLTGGS VSTIKNLGLY STNKHLAWDL MNRYNTFYSM IVEPKVPFTR
NZ2_B2 FWLSDAGHWY VGSASLTGGS VSTIKNLGLY STNKHLAWDL MNRYNTFYSM IVEPKVPFTR
D1701_B2 LCCAVVTPTA TNFHLNHSGG GVFFSDSPER FLGFYRTLDE DLVLHRIENA KNSIDLSLLS
NZ2_B2 LCCAIVTPTA TNFHLDHSGG GVFFSDSPER FLGFYRTLDE DLVLHRIENA KNSIDLSLLS
D1701_B2 MVPVIKHAGA VEYWPRIIDA LLRAAINRGV RVRVIITEWK NADPLSVSAA RSLDDFGVGS
NZ2_B2 MVPVIKHASA VEYWPQIIDA LLRAAINRGV RVRVIITEWK NADPLSVSAA RSLDDFGVGS
D1701_B2 VDMSVRKFVV PGRDDAANNT KLLIVDDTFA HLTVANLDGT HYRYHAFVSV NAEKGDIVKD
NZ2_B2 VDMSVRKFVV PGRDDAANNT KLLIVDDTFA HLTVANLDGT HYRYHAFVSV NAEKGDIVKD
D1701_B2 LSAVFERDWR SEFCKPIN
NZ2_B2 LSAVFERDWR SEFCKPIN
1Amino acid differences are underlined.
2Key residues of PLD domain are italicized.
Table 2 Sequence of the highly conserved region IV of
phospholipase D1 family members found in parapox and
vaccinia viruses
PLD1 family member PLD1 domain amino acid sequence
ORFV B2 NT *KLLIVDDTFA *HLTVANLDGT HY
VACV F131 NN TKLLIVDDEY* VHITSANFDGT HY
1Amino acid differences in the VACV domain sequence relative to the ORFV
sequence are underlined
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denaturation at 95°C, 1 min annealing at 55°C and 1 min
extension at 72°C. This was followed by 10 cycles of 1 min
denaturation at 94°C, 1 min annealing at 55°C and 1 min
extension at 72°C and 24 cycles of 1 min at 94°C, 1 min at
50°C and 1 min at 72°C. The PCR was finished with a 5
min extension at 72°C. All PCR products were assessed by
electrophoresis in 1.2% agarose gels and DNA concentra-
tion was determined using a Hoeffer fluorometer and
Hoechst dye and plasmid DNA as standard.
PCR amplification of each ORF from the genomic tem-
plate yielded 257 specific products of the correct lengths
and high yields. Amplification reaction products for the
remaining ORFs did not meet these criteria so were not
included in the library. The untested ORFs represent 12%
of our annotated list and a similar proportion of the
ORFV ORF homologs in the NCBI database (26 of 134).
The library of 257 ORFV ORFs was randomly partitioned
into 27 pools, each comprised of 8 to 10 ORFs. Batches of
CMV promoter and hGH terminator fragments were gen-
erated by PCR with dU-carrying primers, as described for
the ORFs. The downstream end sequence of the promoter
element and the upstream end sequence of the terminator
sequence were designed such that Uracil DNA-glycosylase
(UDG) treatment would expose 3’ single stranded
stretches complementary to a 3’ overhang on the corre-
sponding ORF ends.
Preparation of ORFV LEE library
The quantitated and quality-confirmed ORF PCR products
were pooled (400 ng of each) into groups of 8 to 10 and
then purified using Qiaquick spin columns per supplied
protocols (Qiagen, Inc., Valencia, CA). The purified DNA
pools were eluted from the columns in 50 μl 10 mM Tris-
HCl, pH 8.5. The CMV promoter and the hGH terminator
elements were combined at an equal molar ratio with each
of the 27 ORF pools (1 μg). UDG (O.5 unit) was added in
a final volume of 50 μl 1X Buffer C (Promega Corp., Madi-
son, WI). The samples were incubated at 37°C for at least
30 min, heated to 75°C for 15 min and mixed with an
equal volume of 1 M KCl. After incubating an additional
15 min at 72°C, the components were allowed to anneal
by slowly cooling to room temperature. The assembled
LEEs were precipitated by the addition of 1/10 volume of
sodium acetate and 2 volumes of ethanol. The precipitated
DNA was collected by centrifugation and washed with
70% ethanol and allowed to dry before it was resuspended
in water and loaded on gold for biolistic inoculation into
abdominal skin [24].
Gene gun inoculation and skin sampling for library
testing
The desired amount of total DNA was precipitated onto
gold beads using a calcium-spermidine protocol pre-
viously described [6]. The DNA-gold complexes were
then spotted onto kapton membranes and dried (2 μg
total DNA per kapton). The complexes were loaded into
cartridges and delivered into mouse abdominal skin that
had been prepared by treatment with shears and Nair
depilatory using a custom hand held gene gun (Rumsey-
Loomis, Ithaca, NY). Each BALB/c mouse was inoculated
(shot) with DNA-gold complexes at 4 to 6 distinct
abdominal skin locations, and each shot carried a differ-
ent LEE pool. Each inoculum was delivered into 3 differ-
ent mice to serve as biological replicates for each pool
test. The sites of inoculation were evaluated 4 days later.
Mice were euthanized and the inoculation sites were iso-
lated; visible gold particles facilitated relocation of shot
sites. Skin segments were trimmed of surrounding tissue
and then immersed in cryoprotective medium and
quickly frozen in liquid nitrogen. Thin-sections (8 μm)
were cut in a Leitz cryostat, picked up on Superfrost plus
microscope slides and stored at -20°C for subsequent
fixation and staining.
Frozen sections were equilibrated to room temperature
for 10 min then fixed by immersion in cold acetone for
10 min. The fixed sections were washed 3 times in phos-
phate buffered saline pH 7.3 (PBS). Non-specific adher-
ence of rat IgG was blocked by treatment of the sections
with a cocktail of Fc block reagent and rat IgG in PBS.
After a 30-min incubation at room temperature, this
blocking solution was replaced by FITC-conjugated rat
anti-I-Ad/I-Ed antibody (2G9) and incubation continued
for 2 hours. The sections were washed 3 times in PBS and
prepared for viewing by the addition of Vectashield
mounting medium and a cover slip. The stained sections
were viewed under white light to locate the area of gene
gun inoculation marked by the presence of gold beads.
These areas were then assessed for the presence of DC-
like immune cells (FITC-labeled, anti-I-Ad/I-Ed antibody
positive cells with DC morphology) under fluorescent
microscopy.
Protein production, purification, and inoculations
The B2L ORF was amplified by PCR using D1701 strain
DNA template and ligated in frame with a His6 tag-encod-
ing sequence into the pQE60 vector (Qiagen Corp.) for
expression and isolation of recombinant protein. The NZ-2
homolog was also amplified from genomic DNA (gift of
Tobias Schlapp of Bayer Pharmaceuticals) and cloned into
pQE60 for expression with a C-terminal 6-histidine (His6)
tag. The yeast SRB4 gene was similarly cloned into pQE60
and produced as an irrelevant, similarly sized, His-tagged
control protein. Plasmids were transformed into E. coli
strain BL21, induced with 0.5 mM IPTG (Isopropyl b-D-1-
thiogalactopyranoside) and cultured by standard protocols.
The recombinant proteins were purified from bacterial
extracts (B-Per, Pierce Chemical Co) using Ni-affinity chro-
matography and imidazole elution. Isolated proteins were
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dialyzed vs PBS + 10% glycerol. L and R designations are
typically used to designate genomic positions of poxvirus
genes, but not included in the nomenclature when the pro-
tein is indicated. Neither B2 nor the control protein sam-
ples contained detectable endotoxin by the amoebocyte
lysate gelling assay. Hair was clipped from the site prior to
protein injection. In initial tests, the recombinant protein
was diluted with sterile PBS and injected intradermally
(i.d.) into the abdomen at various concentrations ranging
from 0.01-10 μg/ml, 50 μl/site. Inoculation sites were
marked with India ink to facilitate subsequent tissue har-
vesting. A total dose of 50 ng/injection was found to be
optimal for measuring cell accumulation. Tissues were
harvested and assayed for DC recruitment as described
following genetic inoculations.
Serum antibody assay
To measure antibody response levels, blood was collected
from each mouse at indicated time-points post immuniza-
tion and assayed for antigen-specific antibodies by ELISA.
Assay plates were coated with HBsAg (Seradyn, Inc.,
Indianapolis, IA) in PBS (10 ng/ml; 50 μl/well) overnight
at 4°C. After the antigen solution was removed, plates
were washed 3 times, blocked with 1% BSA in wash buffer
and incubated with diluted mouse sera. The plates were
washed and antigen-bound antibodies were incubated
with goat anti-mouse-Ig-HRP conjugate (BioRad, Inc.).
Plates were washed again and developed with 100 μl TMB
substrate solution. HRP reactions were stopped by addi-
tion of an equal volume of 0.25 N HCl and absorbance at
450 nm was determined for each well. These absorbance
values were plotted against a standard curve. The standard
curve was derived by measuring reactivity of a dilution ser-
ies of know amounts (ng/ml) of a commercially available
murine monoclonal anti-HBsAg antibody (Seradyn, Inc.).
Influenza challenge-protection assay
The influenza challenge experiment was conducted as part
of a cooperative agreement with the University of New
Mexico, supervised by C. Rick Lyons. Female BALB/c
mice 4-6 weeks of age were purchased from Charles Rivers
Laboratories (Wilmington, MA) and housed in a pathogen
free environment at the University of New Mexico animal
facility for at least 2 weeks before starting the experiments.
All mice were maintained and cared for according to the
guidelines of the institutional Animal Care and Use Com-
mittee. Mice (10 per group) were immunized twice (weeks
0 and 3) with plasmid encoding influenza hemagglutinin,
pCMVi-HA (A/PR/8/34) [45]. Groups of 8 mice were
immunized with one of four doses (0.4, 4 ng, 40 ng,
400 ng) of pCMVi-HA plasmid and either 1 μg control
plasmid (pUC119), pCMVi-GMCSF, or pCMVi-B2L
(D1701 strain). DNA doses are given per mouse; however,
DNA was delivered in 2 shots of half-dose to each ear. For
viral challenge (6 weeks post-boost) isofluorane-anesthe-
tized mice were intranasally administered (in 50 μl PBS
drops) 5 LD50 (= 2.4 × 10
4 50% egg-infecting dose, EID50)
of mouse adapted influenza A/PR/8/34 (H1N1) (Advanced
Biotechnology Inc.), as previously described [45]. The
mice were monitored daily for 23 days post-challenge and
mortality was recorded.
Tumor protection assay
The effect of B2L on tumor development was evaluated in
a transplantable model of melanoma. On day 1, two
groups of 20 C57BL/6 mice were subcutaneously (s.c.)
injected with 5 × 104 of the murine melanoma B16-F10
cells (American Type Culture Collection, Rockville, MD).
The B16-F10 cells were grown in Minimal Essential Med-
ium (MEM; Gibco, Rockville, MD), supplemented with 2
mM L-glutamine, 25 mM HEPES, 2.2 mg/ml sodium
bicarbonate containing 10% FBS (Gibco), 100 U/ml peni-
cillin, 100 μg/ml streptomycin, and 0.11 mg/ml sodium
pyruvate solution (all from Sigma, St. Louis, MO). The
cells were cultured in a humidified, 5% CO2 atmosphere at
37°C. On day 2, the test group was biolistically adminis-
tered pCMVi-B2L as 4 shots of gene gun microparticles
carrying 1 μg of DNA each (Helios, BioRad, Inc.). Tumor
diameters were measured with a micronomer in triplicate
by two individuals at indicated days post tumor cell injec-
tion. At day 13, mice began to be euthanized due to overly
large tumors. Survival was monitored until day 25, and
then all survivors were sacrificed. This experiment was
repeated in this C57BL/6 transplantable melanoma model
and also conducted in a BALB/c transplantable breast
tumor model of cancer.
Animal protocols
For the ORFV DNA and protein injections and for the
influenza challenge-protection experiments six- to eight-
week old female BALB/c mice were purchased from
Charles River Laboratories, San Diego, CA. For the tumor
-protection studies six- to eight-week old female C57BL/6
mice were purchased from Harlan Sprague Dawley, India-
napolis, IN. All mice were housed in a pathogen-free envir-
onment at either the University of Texas Southwestern
Medical Center or the University of New Mexico. Mice
were given food and water ad libitum, and all procedures
were conducted under protocols approved by the Institu-
tional Animal Care and Use Committees and in accor-
dance with federal guidelines for animal experimentation.
Statistical methods
Unpaired Students t tests were used to compare the anti-
body levels measured in the ELISA experiments and also
to compare the tumor sizes of treated and untreated
mice. The relatively small sample sizes (5 to 20 mice per
group) and two-way comparisons of these experiments
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indicate the appropriateness of the t test, although other
less stringent methods might be applied. The arithmetic
mean is calculated for each group and the standard
deviation (SD) used as a measure of variance, these are
indicated by error bars for each plot. For the survival
experiments, Kaplan-Meier survival curves were derived
and the associated parametric test provided by the
PRISM software package (Graphpad).
Additional material
Additional file 1: The B2 protein of ORFV strain NZ2 also displays
immune-cell accumulating activity following murine skin inoculation.
Mice were injected i.d into the abdomen with PBS (left panel) or 50 ng rB2
protein (right panel) in triplicate. After 4 days, immune cell densities were
measured in harvested skin by 2G9 immunostaining, as described in Figures
2 and 3. Scale bars are 40 micron.
Additional file 2: No detectable antibody response to B2 is elicited
by mice co-immunized with rHBsAg and rB2. Sera from the same
groups of mice (4 to 5 per group) assayed for HBsAg-reactivity in Figure
4b were assayed for reactivity to B2. The ELISA was conducted in
duplicate as described in Material and Methods and Figure 4b except
plates were coated with rB2 (50 μl/well) instead of HBsAg.
List of abbreviations
LEE: linear expression element; Interferon-γ: γ-IFN; ORFV: Parapoxvirus ovis;
LUC: luciferase; AAT: α-1 antitrypsin; MHC: major histocompatibility; ORF:
open-reading frame; HA: hemagglutinin; DC: dendritic cells; HBsAg: hepatits
B virus surface antigen.
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